May 13, 2008 - Boston Scientific reported that the FDA cleared its COGNIS cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN implantable cardioverter defibrillator (ICD), enabling the company to introduce new platforms to treat heart failure and sudden cardiac death.
